What does lichen sclerosus look like and feel like?

Classic vulvar lichen sclerosus presents as ivory-white, crinkly atrophic plaques in a figure-of-eight distribution around the labia minora, clitoral hood, and perianal area. Patients typically describe intense itching — often worse at night — along with pain with sex, pain with urination, anal fissures, and fragile skin that bruises or cracks after minor trauma. Over time, architectural changes develop: the labia minora fuse to the labia majora, the clitoral hood tightens over the clitoris, and the vaginal opening narrows. These changes are largely preventable with early and consistent treatment with a potent topical corticosteroid.

How is clobetasol applied for lichen sclerosus?

The British Association of Dermatologists 2018 protocol is the standard used in Australian dermatology practice: apply clobetasol propionate 0.05% ointment nightly to the affected area for 4 weeks, then on alternate nights for a further 4 weeks, then twice weekly for at least 4 weeks. Most patients continue twice-weekly maintenance long-term to prevent flares. A 30 g tube lasts approximately 12 weeks when a pea-sized amount is used per application. Teaching application technique is as important as prescribing — patients often apply too little or to the wrong area. Ointment base is preferred over cream for genital skin.

Does lichen sclerosus cause cancer?

Lichen sclerosus carries a 2–6% lifetime risk of vulvar squamous cell carcinoma (SCC), which is substantially higher than background population risk. Effective treatment with clobetasol reduces but does not eliminate this risk — which is why lifelong 6–12-monthly surveillance is recommended for all patients with lichen sclerosus. At each review, the GP or dermatologist looks for any new firm, fixed, ulcerated, thickened, or non-healing area that warrants biopsy. Patients are also taught to self-examine and to return promptly if a new lump, sore, or bleeding area develops between scheduled visits.

Is lichen sclerosus connected to other autoimmune conditions?

Yes. Lichen sclerosus is associated with several autoimmune conditions including autoimmune thyroid disease, type 1 diabetes, vitiligo, alopecia areata, and pernicious anaemia. About one in four patients has a family history of lichen sclerosus or another autoimmune condition. Checking thyroid function tests at diagnosis is reasonable, particularly if symptoms suggest thyroid disease. The condition itself involves a T-cell-mediated chronic inflammatory process, with anti-extracellular matrix protein 1 (ECM-1) antibodies found in some patients, supporting an autoimmune aetiology.

Can lichen sclerosus affect children?

Yes — around 5–7% of prepubertal girls presenting with vulval symptoms have lichen sclerosus. Childhood lichen sclerosus can be confused with sexual abuse because pathergy (Köbner phenomenon at sites of minor trauma) causes bruising, fissuring, and ecchymoses that may appear to be injury. Specialist paediatric assessment is appropriate whenever there is any uncertainty about the cause. Treatment with clobetasol is the same as in adults. Some girls improve significantly at puberty when oestrogen rises, though a proportion continue into adulthood and require ongoing monitoring and maintenance treatment.

Lichen sclerosus

Lichen sclerosus: recognition, clobetasol treatment, and lifelong surveillance

By Dr HB Lo, FACRRM Reviewed 22 June 2026 8 min read

Lichen sclerosus is a chronic inflammatory skin condition most commonly affecting the vulva or penis, with a bimodal age peak in prepubertal girls and post-menopausal women. Roughly 1–3% of Australian post-menopausal women are affected, and diagnosis is frequently delayed by several years.

First-line treatment is clobetasol propionate 0.05% ointment applied in a structured induction–step-down schedule. When used correctly it controls symptoms, prevents architectural damage, and substantially reduces the 2–6% lifetime risk of vulvar squamous cell carcinoma.

Lifelong 6–12-monthly surveillance for malignant change is required for all patients, even when symptoms are well controlled.

What lichen sclerosus is — and why it gets missed for years

Lichen sclerosus is a chronic relapsing-remitting inflammatory skin disorder that most commonly affects the anogenital region. The vulva is involved in approximately 85% of cases, producing the characteristic ivory-white atrophic plaques with a crinkly surface in a figure-of-eight distribution around the labia minora, clitoral hood, and perianal skin. The penis (glans and inner foreskin) is the next most common site, and in a minority of patients extragenital skin — upper trunk, breast, axillae, wrists — is also involved.

The condition is frequently underdiagnosed. Median delay from symptom onset to diagnosis is 4–5 years in Australian and international series. Patients present with chronic vulval pruritus — often severe, worse at night — and are sometimes told they have recurrent thrush, contact dermatitis, or “nothing abnormal found.” The diagnosis requires clinical examination of the genitalia with adequate lighting, a willingness to look, and familiarity with the clinical picture.

Prevalence is approximately 1–3% in post-menopausal Australian women, with a bimodal age peak in prepubertal girls (around 5–7% of girls with vulval symptoms) and post-menopausal women. The female-to-male ratio for vulvar disease is roughly 10:1. The Australasian College of Dermatologists and the British Association of Dermatologists 2018 guideline are the two cornerstone references for Australian practice.

A. Core clinical — the AU general-practice framework

History and symptoms to ask about

Lichen sclerosus rarely volunteers itself. The clinical history should specifically probe:

Pruritus — onset, duration, severity, nocturnal worsening, response to over-the-counter creams
Dyspareunia — superficial at the introitus; progressive restriction of penetration
Dysuria — meatal involvement or periurethral fissures
Anal symptoms — fissures, bleeding, painful defecation, soiling
Skin fragility — easy bruising, tearing, bleeding with minor trauma or intercourse
Previous diagnoses — prior treatment for “candida,” contact dermatitis, or “sensitive skin” that did not fully resolve
Autoimmune comorbidities — thyroid disease, type 1 diabetes, vitiligo, alopecia, pernicious anaemia
Family history of lichen sclerosus or autoimmune disease

In men and boys, ask specifically about foreskin tightness (phimosis), inability to retract the foreskin, glans changes, and painful intercourse.

Examination

Examination with a chaperone, in good lighting, is essential. eTG Dermatology and RACGP resources both emphasise that genital lichen sclerosus is a clinical diagnosis in classic presentations, without need for biopsy. Key findings to document:

Ivory-white atrophic plaques with crinkled or cigarette-paper surface
Figure-of-eight distribution around vulva and perianal area
Architectural change — fusion of labia minora to labia majora, clitoral phimosis (clitoris hidden under fused hood), introital narrowing or stenosis
Telangiectasias, purpura, ecchymoses, fissures — hallmarks of fragile skin
Hyperkeratotic or nodular areas — require biopsy to exclude squamous cell carcinoma

Biopsy (MBS item 30196) is reserved for: atypical appearances; hyperkeratotic, thickened, or nodular areas; failure to respond to potent topical corticosteroid after adequate trial; or diagnostic uncertainty.

Treatment — the clobetasol protocol

The cornerstone of management is clobetasol propionate 0.05% ointment (PBS-listed, general schedule). The BAD 2018 protocol, adopted by the Australasian College of Dermatologists:

Induction (weeks 1–4): apply nightly to affected area
Step-down (weeks 5–8): apply on alternate nights
Maintenance step-down (weeks 9–12): apply twice weekly
Long-term maintenance: twice weekly ongoing, adjusting up during flares

Application teaching is critical: a pea-sized amount for the entire vulva; patted gently rather than rubbed; ointment base preferred over cream for genital mucosa. A 30 g tube at this application rate lasts approximately 12 weeks. Lee et al. (Br J Dermatol 2015) demonstrated that proactive twice-weekly maintenance reduces flare frequency and may reduce long-term SCC risk.

Adjunct measures: soft white paraffin or zinc oxide as barrier emollient; avoidance of irritants (perfumed soaps, douching, scented sanitary products, abrasive fabrics); cotton loose-fitting underwear.

First-line investigations at diagnosis

Thyroid function tests — autoimmune thyroid co-exists in a substantial minority
HbA1c or fasting glucose — type 1 diabetes association
Skin biopsy — only if indications above are met; not routine
STI screen if clinically indicated

B. The 2–6% cancer risk and why surveillance matters

Lichen sclerosus is associated with a 2–6% lifetime risk of vulvar squamous cell carcinoma in patients with persistent or inadequately treated disease. The European S3 guideline 2023 and the BAD 2018 guideline both classify this as a clinically significant risk requiring structured surveillance for life.

The mechanism is chronic inflammation driving epithelial dysplasia — particularly differentiated vulvar intraepithelial neoplasia (dVIN), which is HPV-independent and lichen-sclerosus-related. The risk is substantially lower in patients whose disease is well controlled with topical steroid — which provides a compelling clinical rationale for adherence.

Surveillance protocol per BAD 2018 and ACD:

6-week review after initiating clobetasol to assess treatment response
3-monthly during dose titration
6–12-monthly long-term for life — examination of the vulvar, penile or perianal area
Biopsy any new firm, fixed, ulcerated, thickened, hyperkeratotic, or non-resolving area
Teach patient self-examination: what to look for, when to return urgently

Patients should be explicitly told that the surveillance schedule continues even when they feel completely well — this is one of the most important education messages in lichen sclerosus care.

C. Differential diagnosis and when to suspect something else

The main differential diagnoses in clinical practice:

Condition	Key discriminator
Vulvovaginal candidiasis	Acute onset, discharge, resolves with antifungal
Contact or atopic dermatitis	Known irritant exposure, atopy history, pattern distribution
Vulvar psoriasis	Salmon-pink well-demarcated plaques; look for other body sites
Lichen planus (erosive)	Erosions, Wickham striae, oral involvement; biopsy distinguishes
Vulvar intraepithelial neoplasia (VIN)	Thickened, raised lesion; biopsy mandatory
Vulvar SCC	Mass, ulceration, induration; biopsy urgently
Post-menopausal atrophic vaginitis	GSM context; responds to topical oestrogen; may co-exist
Childhood sexual abuse	Bruising pattern may overlap; specialist paediatric assessment

When lichen sclerosus does not respond as expected to clobetasol after 6–8 weeks of proper use, suspect an alternative diagnosis, superimposed infection, poor technique, or a co-existing condition. Biopsy at that point is appropriate.

D. Australian operations

PBS-listed treatments:

Clobetasol propionate 0.05% ointment — general schedule; affordable and accessible
Tacrolimus 0.03% / 0.1% ointment — PBS Authority for atopic dermatitis; off-label for lichen sclerosus (private script); useful as steroid-sparing in patients who develop steroid atrophy concerns or are refractory
Topical oestrogen (vaginal) — general schedule for post-menopausal atrophic vaginitis co-existing with lichen sclerosus

MBS items relevant to lichen sclerosus management:

Standard consultations (items 23 / 36 / 44) for examination and counselling
Skin biopsy (item 30196) when indicated
GPCCMP (items 965 / 967) for chronic disease management planning
MHCP (items 2715 / 2717) for patients with sexual function or psychological impact from chronic disease
ATSI health assessment (item 715)

Referral pathways:

Routine referral to dermatology or gynaecology for chronic refractory disease, need for biopsy, or surgical complications
Semi-urgent referral for any new suspicious lesion requiring same-day or early biopsy
Pelvic floor physiotherapy for introital narrowing, vaginismus, or dyspareunia
Surgery (lysis of fused labia, introitoplasty, circumcision for penile disease, wide local excision for confirmed malignancy) is specialist-directed

Consumer resources: Jean Hailes for Women’s Health, HealthDirect, Better Health Channel, and the Lichen Sclerosus Australia consumer support community.

E. Special populations

Post-menopausal women. Oestrogen deficiency contributes to vulvovaginal atrophy that can co-exist with lichen sclerosus — distinguishing or managing both simultaneously matters. Topical oestrogen is safe to use alongside clobetasol for the atrophic component. Avoid diagnosing “just atrophy” without examining for the characteristic lichen sclerosus plaques.

Prepubertal girls. Management is the same clobetasol protocol. Specialist paediatric dermatology or paediatric gynaecology input is appropriate for severe, atypical, or diagnostically uncertain presentations. The differential of sexual abuse should be handled with care — both conditions can produce similar findings, and lichen sclerosus is sometimes mistakenly reported as abuse, and vice versa. A non-judgmental specialist assessment protects the child and the family.

Men and boys — balanitis xerotica obliterans (BXO). Penile lichen sclerosus produces white plaques on the glans and inner foreskin, phimosis, meatal stenosis, and painful sex. Circumcision is frequently required and curative in many cases. Urological referral when phimosis is functionally significant. Ongoing surveillance for penile SCC is required.

Aboriginal and Torres Strait Islander patients. Genital examination in an Indigenous woman should ideally involve a female health worker or chaperone from the community, coordinated through the Aboriginal Community Controlled Health Organisation (ACCHO). Closing the Gap PBS co-payment applies. Cultural safety considerations are part of clinical governance.

CALD communities. Genital examination may require additional explanation and cultural sensitivity. Use of a professional interpreter (TIS National 131 450) rather than a family member for intimate history-taking is recommended.

When to escalate

Refer or escalate when:

Any new firm, ulcerated, hyperkeratotic, fixed, or non-resolving vulvar or penile lesion — biopsy urgently (semi-urgent or urgent dermatology / gynaecology)
Suspected vulvar SCC — same-day referral
Inadequate response to clobetasol after 8–12 weeks of proper technique — review diagnosis; biopsy; dermatology referral
Severe introital narrowing preventing sexual function or gynaecological examination — surgical gynaecology
Penile phimosis causing functional impairment — urology
Significant psychological impact of chronic genital disease, sexual dysfunction, or fear of cancer — MHCP and psychology referral
Children with uncertain diagnosis or severe presentation — paediatric dermatology or paediatric gynaecology

What this article is and is not

This is general health information drawn from current Australian and international guidelines — Therapeutic Guidelines (eTG), RACGP, Australasian College of Dermatologists, and the British Association of Dermatologists 2018 guideline. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about diagnosis, treatment, and surveillance are made with your own GP, dermatologist, or gynaecologist.

For consumer-friendly information: Jean Hailes for Women’s Health, HealthDirect, Better Health Channel.

Sources cited

Frequently asked questions

What does lichen sclerosus look like and feel like?

Classic vulvar lichen sclerosus presents as ivory-white, crinkly atrophic plaques in a figure-of-eight distribution around the labia minora, clitoral hood, and perianal area. Patients typically describe intense itching — often worse at night — along with pain with sex, pain with urination, anal fissures, and fragile skin that bruises or cracks after minor trauma. Over time, architectural changes develop: the labia minora fuse to the labia majora, the clitoral hood tightens over the clitoris, and the vaginal opening narrows. These changes are largely preventable with early and consistent treatment with a potent topical corticosteroid.
How is clobetasol applied for lichen sclerosus?

The British Association of Dermatologists 2018 protocol is the standard used in Australian dermatology practice: apply clobetasol propionate 0.05% ointment nightly to the affected area for 4 weeks, then on alternate nights for a further 4 weeks, then twice weekly for at least 4 weeks. Most patients continue twice-weekly maintenance long-term to prevent flares. A 30 g tube lasts approximately 12 weeks when a pea-sized amount is used per application. Teaching application technique is as important as prescribing — patients often apply too little or to the wrong area. Ointment base is preferred over cream for genital skin.
Does lichen sclerosus cause cancer?

Lichen sclerosus carries a 2–6% lifetime risk of vulvar squamous cell carcinoma (SCC), which is substantially higher than background population risk. Effective treatment with clobetasol reduces but does not eliminate this risk — which is why lifelong 6–12-monthly surveillance is recommended for all patients with lichen sclerosus. At each review, the GP or dermatologist looks for any new firm, fixed, ulcerated, thickened, or non-healing area that warrants biopsy. Patients are also taught to self-examine and to return promptly if a new lump, sore, or bleeding area develops between scheduled visits.
Is lichen sclerosus connected to other autoimmune conditions?

Yes. Lichen sclerosus is associated with several autoimmune conditions including autoimmune thyroid disease, type 1 diabetes, vitiligo, alopecia areata, and pernicious anaemia. About one in four patients has a family history of lichen sclerosus or another autoimmune condition. Checking thyroid function tests at diagnosis is reasonable, particularly if symptoms suggest thyroid disease. The condition itself involves a T-cell-mediated chronic inflammatory process, with anti-extracellular matrix protein 1 (ECM-1) antibodies found in some patients, supporting an autoimmune aetiology.
Can lichen sclerosus affect children?

Yes — around 5–7% of prepubertal girls presenting with vulval symptoms have lichen sclerosus. Childhood lichen sclerosus can be confused with sexual abuse because pathergy (Köbner phenomenon at sites of minor trauma) causes bruising, fissuring, and ecchymoses that may appear to be injury. Specialist paediatric assessment is appropriate whenever there is any uncertainty about the cause. Treatment with clobetasol is the same as in adults. Some girls improve significantly at puberty when oestrogen rises, though a proportion continue into adulthood and require ongoing monitoring and maintenance treatment.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.

T1 AU primary 7 sources
T2 International primary 2 sources
- British Association of Dermatologists — Lichen sclerosus guideline 2018
- European S3 Lichen Sclerosus Guideline 2023
T3 Named-author reconstruction 1 source
- Lee A et al. — Long-term clobetasol propionate in vulvar lichen sclerosus (Br J Dermatol 2015)